These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 21562485)
1. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485 [TBL] [Abstract][Full Text] [Related]
2. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124 [TBL] [Abstract][Full Text] [Related]
3. Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Stamer UM; Musshoff F; Stüber F; Brockmöller J; Steffens M; Tzvetkov MV Pain; 2016 Nov; 157(11):2467-2475. PubMed ID: 27541716 [TBL] [Abstract][Full Text] [Related]
4. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346 [TBL] [Abstract][Full Text] [Related]
5. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Tzvetkov MV; dos Santos Pereira JN; Meineke I; Saadatmand AR; Stingl JC; Brockmöller J Biochem Pharmacol; 2013 Sep; 86(5):666-78. PubMed ID: 23835420 [TBL] [Abstract][Full Text] [Related]
6. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Tzvetkov MV; Saadatmand AR; Bokelmann K; Meineke I; Kaiser R; Brockmöller J Pharmacogenomics J; 2012 Feb; 12(1):22-9. PubMed ID: 20921968 [TBL] [Abstract][Full Text] [Related]
7. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients. Halling J; Weihe P; Brosen K Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597 [TBL] [Abstract][Full Text] [Related]
8. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients. Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604 [TBL] [Abstract][Full Text] [Related]
9. SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Matic M; de Wildt SN; Elens L; de Hoon JN; Annaert P; Tibboel D; van Schaik RH; Allegaert K Ther Drug Monit; 2016 Aug; 38(4):487-92. PubMed ID: 27082504 [TBL] [Abstract][Full Text] [Related]
10. Pupillometry in healthy volunteers as a biomarker of tramadol efficacy. Matouskova O; Slanar O; Chytil L; Perlik F J Clin Pharm Ther; 2011 Aug; 36(4):513-7. PubMed ID: 21729116 [TBL] [Abstract][Full Text] [Related]
11. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744 [TBL] [Abstract][Full Text] [Related]
12. OCT1 pharmacogenetics in pain management: is a clinical application within reach? Tzvetkov MV Pharmacogenomics; 2017 Nov; 18(16):1515-1523. PubMed ID: 29061087 [TBL] [Abstract][Full Text] [Related]
13. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Saadatmand AR; Tadjerpisheh S; Brockmöller J; Tzvetkov MV Biochem Pharmacol; 2012 May; 83(10):1427-34. PubMed ID: 22342776 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. de Sousa AB; Santos AC; Schramm SG; Porta V; Górniak SL; Florio JC; de Souza Spinosa H J Vet Pharmacol Ther; 2008 Feb; 31(1):45-51. PubMed ID: 18177318 [TBL] [Abstract][Full Text] [Related]
15. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026 [TBL] [Abstract][Full Text] [Related]
16. CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response. Slanar O; Nobilis M; Kvetina J; Idle JR; Perlík F Eur J Clin Pharmacol; 2006 Jan; 62(1):75-6; author reply 77-8. PubMed ID: 16283276 [No Abstract] [Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats. Valle M; Garrido MJ; Pavón JM; Calvo R; Trocóniz IF J Pharmacol Exp Ther; 2000 May; 293(2):646-53. PubMed ID: 10773040 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose. Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. Stewart AJ; Boothe DM; Cruz-Espindola C; Mitchum EJ; Springfield J Am J Vet Res; 2011 Jul; 72(7):967-74. PubMed ID: 21728858 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]